Drug intelligence / Profile preview

RIPK1 inhibitor (Belfer Neurodegeneration Consortium)

Development stage: Preclinical
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is being developed by the Belfer Neurodegeneration Consortium (BNC) at MD Anderson Cancer Center. RIPK1 is a critical mediator of necroptosis (programmed inflammatory cell death) and pro-inflammatory signaling pathways. By inhibiting RIPK1, the compound aims to reduce neuroinflammation and neuronal loss. The primary indications under investigation include Alzheimer's disease and the prevention or treatment of brain inflammation following radiation therapy for brain tumors. The project is currently in the preclinical stage of development.

Other names: RIPK1 inhibitor (MD Anderson)BNC RIPK1 inhibitor

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on RIPK1 inhibitor (Belfer Neurodegeneration Consortium).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIPK1 inhibitor (Belfer Neurodegeneration Consortium).

Explore the full profile